Have you dreamed of a skincare product promising youth-preserving results only to be let down time and time again? Now you can make that dream a reality, as USANA launches its high-performance skincare system, Celavive®. This unique line is fueled by USANA InCelligence Technology®, a combination of powerful peptides, botanicals and key nutrients that talk to your skin’s cells to target your unique beauty needs.
As we age, our cellular function slows and becomes less effective, resulting in wrinkles and loss of firmness. By tapping into USANA InCelligence Technology, Celavive is able to signal your beauty-preserving functions to support your natural ability to retain moisture from within. It also supports other key elements that help contribute to a younger-looking complexion.
To view the multimedia release go to:
https://www.multivu.com/players/English/7736552-usana-celavive-skincare-line/
Nearly 90 percent of children and adults with a highly aggressive form of acute lymphoblastic leukemia (ALL) showed no evidence of cancer after receiving a novel, personalized cell therapy that reprograms a patient’s immune system. In pilot studies of bioengineered T cells that attack leukemia, 24 of 27 patients (89%) experienced complete responses within 28 days after treatment. In all, 27 patients received the treatment--22 children treated at The Children’s Hospital of Philadelphia and five adults treated at the Hospital of the University of Pennsylvania.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64394-chop-penn-harness-engineered-t-cells-eliminate-tumors-in-blood-leukemia
Sutter Neuroscience Institute, a recognized Center of Excellence, and CBR (Cord Blood Registry), the world’s largest stem cell bank, are launching the first FDA- approved clinical trial to assess the use of a child’s own cord blood stem cells to treat select patients with autism. This first-of-its-kind placebo controlled study will evaluate the ability of an infusion of cord blood stem cells to help improve language and behavior. The study is in conjunction with the Sutter Institute for Medical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57707-cord-blood-registry-stem-cell-trials-child-autism
Tony tells us how he totally removed the pre cancerous Actinic Keratosis from his FACE at home in only 14 DAYS using www.Ag3derm.com cream he applied the cream 2 x times Daily and the abnormal cells were destroyed leaving fresh new pink skin that slowly blended in withhis surrounding skin.
2017 Renault Zoe
Renault has introduced a new Z.E. 40 battery for ZOE. At the same, ZOE owners can benefit from a range of new connected services and equipment upgrades. Order books for the new ZOE line-up are open. The new ZOEs fitted with the new Z.E. 40 battery are made at Renault's Flins plant in France and will be available for delivery before the end of 2016.
Double the range for even longer journeys
As the pioneer of all-electric mobility and Europe's number one seller of electric vehicles, Renault has stepped up its innovation programme and the deployment of its Zero Emissions strategy.
Fitted with the new Z.E. 40 battery, the Renault ZOE now delivers a record NEDC driving range of 400km, which is twice the distance delivered by the model at the time of its original launch.
The new Z.E. 40 battery has a real-world range of 300 kilometres in urban or suburban areas, for example.
The range permitted today by the ZOE is the longest of any mainstream all-electric vehicle and motorists can take advantage of this step forward now.
The ZOE is the best-selling electric vehicle in Europe and provides a real alternative to internal combustion-engine cars, since average daily commuting distances are well within the ZOE's capabilities.
The new battery removes the final psychological barrier that stands in the way of buying an electric car since ZOE users can now travel further and enjoy a wider variety of driving situations without worry about charging. This makes weekend trips a real possibility.
The Z.E. 40 battery's charging rate is similar to that of the standard battery, so 'topping up' doesn't take long at all. For example, just 30 minutes are required on average to charge the battery for an extra 80 kilometres of driving range when plugged into one of the many public charging points in operation in Europe. The ZOE continues to be equipped with the Quick Charge function to take full advantage of the maximum capacity of fast charging points located predominantly along motorway corridors.
An innovation that doubles battery capacity with no increase in size
The ZOE's new Z.E. 40 battery boasts 41kWh of useful energy, equivalent to almost double the storage capacity of the ZOE's standard battery (22kWh of useful energy).
Developed in close partnership with LG Chem, the battery uses high-energy density lithium-ion technology.
Renault and LG engineers have succeeded in increasing storage capacity without making the battery any bigger or a lot heavier. It was optimised by working on the chemistry of the cells in order to increase their energy density, rather than stacking additional battery modules, a commonly used technique.
This major new technology has been developed while ensuring the battery's reliability or safety.
The battery's large storage capacity ensures longer range for the ZOE thanks to the meticulous work that went into integrating the battery in the vehicle. The electronic management system of the battery optimises the ZOE's energy use on the move, while the new air circulation system maintains the temperature of the ZOE's battery at a constant level, making the car economical to run in very hot or very cold weather.
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
